an experimental experience

12/15/22 at 11:04pm

Organization

Author

Vishnu Priyan

31 words

Comments

The EC has granted expanded marketing authorisation for Sanofi’s Dupixent (dupilumab) for the treatment of prurigo nodularis in adults.

You are the first to view

http://www.pharmaceutical-technology.com/news/ec-approves-sanofi-dupixent/

Create an account or login to join the discussion